[Special Stock] Performance Meets Expectations... Hugel Rises Over 5%

Hugel's stock price is on the rise following fourth-quarter results last year that met market expectations. Based on the performance of botulinum toxin and other factors, the company's full-year results set a new record high.

As of 9:07 AM on the 14th, Hugel was trading at 272,500 KRW, up 13,500 KRW from the previous trading day.

In the fourth quarter of last year, Hugel's sales reached 98.2 billion KRW, and operating profit was 46.6 billion KRW, representing increases of 10.4% and 26.7% respectively compared to the same period the previous year, aligning with market consensus estimates. Consequently, the company achieved record-high full-year sales of 373 billion KRW and operating profit of 166.3 billion KRW.

On the same day, Samsung Securities maintained a target price of 400,000 KRW and a buy rating for Hugel.

Jung Dong-hee, a researcher at Samsung Securities, analyzed, "As confirmed by export data, there was no additional shipment of U.S. toxin compared to the high base formed in the third quarter, but the inclusion of shipments to China in October last year (estimated at about 10 billion KRW), recovery in Asian filler sales, and high growth in cosmetics sales contributed to a 10.5% year-on-year increase in total company sales. Along with efficient management of key accounts such as labor and advertising costs, and controlling selling and administrative expenses, the operating profit margin reached 47.4%."